RE: Cash Runway30 Apr 2020 16:41
Hi Ghia,
They raised £22m in the placing 18 Feb, it was for 18m (minimum) but was so oversubscribed they took 22m. Merck took 3.83m and the directors £2m. The bookbuild was announced and completed the same day. The warrants, always a concern, have a 5 year lock in at £1 issued on a 1 warrant for 2 share basis. No wonder it was oversubscribed!
In terms of cash runway, the last placing was 2015, which is some achievement for a biotech, but the SP has tanked from £10 days to what it’s is now. They have made it clear that any ‘further funding will be via partnering’. Punters are obviously backing Merck.
The finals will be pretty meaningless, R&D probably around 22m and they had cash before the placing but the placing and obviously the dilution changes everything. They, BoD, have a high degree of confidence in the impending readouts....
“Subject to reporting positive data from these studies, the Company believes these will provide a material validation for its approach to developing LBPs and also serve as value accretive events for Shareholders.”
Sure there is a seller at the moment, there tends to be after a placing. But they are now fully funded and can concentrate on the science....
As risky as bio’s are this is probably a good time to buy, against a seller, cashed up and news not too far off. Obviously DYOR.
Trek